Can a diabetic patient be treated with both an ACE inhibitor (angiotensin‑converting enzyme inhibitor) and an ARB (angiotensin II receptor blocker) simultaneously?

No – Diabetic Patients Should NOT Take ACE Inhibitors and ARBs Together

The combined use of ACE inhibitors and ARBs should be avoided in diabetic patients. 1 This recommendation is based on clinical trials demonstrating no additional cardiovascular or kidney benefits with combination therapy, while significantly increasing adverse events including hyperkalemia and acute kidney injury.

Evidence Against Combination Therapy

The most authoritative guidance comes from multiple major diabetes and kidney disease guidelines, all reaching the same conclusion:

• American Diabetes Association (2019): Two clinical trials specifically studied ACE inhibitor plus ARB combinations and found no benefits on cardiovascular disease or chronic kidney disease, with higher adverse event rates (hyperkalemia and/or acute kidney injury). 1

• KDIGO Guidelines (2020,2022): Explicitly state that dual therapy should be avoided, with no exceptions recommended even in patients with advanced kidney disease. 2, 3

• Canadian Hypertension Guidelines (2010): The combination of an ACE inhibitor with an ARB is not recommended in patients with diabetes and normal urinary albumin levels. 4

• International Hypertension Guidelines (2014): All reviewed guidelines advised against combining ACE inhibitors and ARBs due to increased risk of end-stage renal disease and stroke identified in the ONTARGET and ALTITUDE studies. 5

The Correct Approach: Monotherapy

Use either an ACE inhibitor OR an ARB – not both. 1, 2, 3

When to Use ACE Inhibitor or ARB:

1. First-line for diabetics with:

   • Hypertension AND albuminuria (≥30 mg/g creatinine) 1, 2, 3
   • eGFR <60 mL/min/1.73 m² AND albuminuria ≥300 mg/g creatinine 1

2. Titrate to maximum tolerated dose – this is critical, as clinical trials demonstrating efficacy used maximum doses, not low doses 6

3. ACE inhibitors and ARBs are considered equivalent in terms of benefits and risks 1

When Additional Blood Pressure Control is Needed:

If blood pressure remains uncontrolled on maximum-dose ACE inhibitor or ARB monotherapy, add:

• Dihydropyridine calcium channel blocker (e.g., amlodipine) 4, 5, 7
• Thiazide-like diuretic (chlorthalidone or indapamide preferred) 4, 5, 7

Never add the other class of renin-angiotensin system blocker (i.e., don't add ARB to ACE inhibitor or vice versa). 1, 7

Common Pitfalls to Avoid

1. Underdosing monotherapy: Many clinicians use subtherapeutic doses of ACE inhibitors or ARBs due to fear of creatinine elevation. This is inappropriate – trials showing benefit used maximum tolerated doses. 6

2. Stopping therapy for minor creatinine increases: Continue ACE inhibitor or ARB unless serum creatinine rises by more than 30% within 4 weeks of initiation or dose increase. 2, 3

3. Misinterpreting older literature: Some older studies suggested combination therapy might reduce proteinuria 8, 9, but these were small, short-term studies that did not assess hard clinical outcomes. The definitive large trials showed harm. 1

Monitoring Requirements

When using ACE inhibitor or ARB monotherapy, monitor within 2-4 weeks of initiation or dose change: 2, 7, 3

• Serum creatinine
• Serum potassium
• Blood pressure

Alternative for Resistant Cases

If additional renin-angiotensin-aldosterone system blockade is needed for resistant hypertension or persistent albuminuria, consider:

• Mineralocorticoid receptor antagonists (finerenone, spironolactone, eplerenone) in combination with ACE inhibitor or ARB 1, 3
• This is an area of active research with emerging evidence for additional cardiovascular and kidney benefits 1
• Monitor potassium closely due to hyperkalemia risk 1